Smoking Cessation Cardiac Programs integrate structured tobacco-dependence treatment within cardiovascular care pathways to reduce recurrent events, improve procedural outcomes and enhance long-term survival. Because smoking remains one of the most powerful modifiable risk factors for coronary artery disease, stroke and peripheral vascular disease, clinicians increasingly seek guidance on building effective, evidence-based programmes. Many teams look for sessions on Smoking Cessation Cardiac Programs when choosing tracks at a cardiology conference that emphasises prevention, rehabilitation and patient engagement. By combining behavioural support, pharmacotherapy and multidisciplinary follow-up, these programmes form a central pillar of comprehensive cardiovascular risk reduction.

The session opens by examining the pathophysiologic impact of tobacco on endothelial function, thrombosis, autonomic tone and myocardial oxygen balance. Participants review data linking continued smoking after myocardial infarction, PCI or CABG to higher reinfarction rates, restenosis, graft failure and mortality. This scientific foundation helps clinicians communicate the urgency of cessation while framing discussions in terms of personalised benefit rather than generic risk messaging.

A major focus is programme design. Participants explore how to embed systematic screening for tobacco use into routine clinic visits, hospital admissions and cardiac rehabilitation sessions. The session describes brief intervention models, motivational interviewing techniques and structured counselling protocols that can be adapted for diverse cultural and literacy contexts. Particular attention is given to addressing ambivalence, previous failed quit attempts and coexisting anxiety or depression, which often complicate cessation efforts.

Pharmacologic support is reviewed in depth, including nicotine replacement therapy, varenicline and bupropion. Clinicians learn how to tailor medication choices to individual cardiovascular risk, comorbidities and previous responses, as well as how to combine behavioural and pharmacologic strategies for maximal success. Considerations for patients with arrhythmias, heart failure or recent acute coronary syndromes are discussed to ensure safe prescribing.

The session also highlights group-based and digital cessation models, such as telehealth counselling, mobile-app support and automated text messaging. Participants discuss how these tools can reinforce clinic-based care, improve adherence and expand reach to rural or underserved populations. Measures of programme quality—quit rates, relapse patterns, patient satisfaction and impact on rehospitalisation—are explored to help teams evaluate and continuously improve their services.

Future directions include personalised cessation plans guided by genetic susceptibility, integration with broader lifestyle programmes targeting diet and exercise, and coordinated initiatives with public health agencies. By the end of this session, clinicians will be equipped to advocate for and implement robust smoking cessation cardiac programs that turn every clinical contact into an opportunity for change, ultimately reducing the heavy cardiovascular burden associated with tobacco use. The overarching message is that smoking cessation is not a peripheral wellness add-on, but a core therapeutic intervention equal in importance to revascularisation, lipid lowering and blood-pressure control in comprehensive cardiac care.